ANI Pharmaceuticals (ANIP) said Monday it has launched Carbamazepine Extended-Release Capsules in 100 mg, 200 mg, and 300 mg doses.
The product is a generic version of Carbatrol and targets a US market with annual sales of about $65 million, the company said, citing IQVIA data.